Randomized Phase IIa Clinical Study of an Anti-α<sub>v</sub>β<sub>6</sub>Monoclonal Antibody in Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Randomized Phase IIa Clinical Study of an Anti-α_vβ₆Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

Published:2022-11-01 Issue:9 Volume:206 Page:1166-1168
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Raghu Ganesh¹,Mouded Majd²,Prasse Antje³,Stebbins Christopher²,Zhao Guolin²,Song Guochen²,Arefayene Million²,Violette Shelia M.²,Gallagher Diana²,Gibson Kevin F.⁴

Affiliation:

1. Center for Interstitial Lung DiseasesUniversity of Washington Medical CenterSeattle, Washington

2. Biogen, Inc.Cambridge, Massachusetts

3. Department of PneumologyMedical School of HannoverHannover, Germany

4. Division of Pulmonary, Allergy, and Critical Care MedicineUniversity of Pittsburgh School of MedicinePittsburgh, Pennsylvania

Funder

Biogen

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202205-0868LE

Reference11 articles.

1. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

2. TGF-β Activation and Lung Fibrosis

3. A Mechanism for Regulating Pulmonary Inflammation and Fibrosis: The Integrin αvβ6 Binds and Activates Latent TGF β1

4. Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation

5. Inhibition of the αvβ6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis;Pharmaceutical Science Advances;2024-12

2. Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α_vβ₆ Integrin Inhibitors;Journal of Medicinal Chemistry;2024-09-13

3. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2024-08-15

4. Evidence from recent clinical trials in fibrotic interstitial lung diseases;Current Opinion in Pulmonary Medicine;2024-07-04

5. Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis;Expert Opinion on Therapeutic Targets;2024-07-02